Loading…
Reported covered position: Senior Policy Advisory, House Majority Leader Eric Cantor, Program Manager, US Department of Justice, Legislative Correspondent, Senator John Ashcroft; Paid Intern, Representative Robert Aderholt
How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
No topic inference: each bill number appears in source LDA issue text assigned to this lobbyist.
To amend the Federal Food, Drug, and Cosmetic Act to increase transparency in generic drug applications.
Client: VIATRIS (MYLAN, INC) · Firm: S-3 GROUP
Issues related to drug pricing; pharmaceutical supply chain; modernization of prescribing information for physicians and pharmacists; Increasing Transparency in Generic Drug Applications, S.1302 and H.R. 1843; Part D Formulary Design and Generic Drug Testing
To amend the Federal Food, Drug, and Cosmetic Act to increase transparency in generic drug applications.
Client: VIATRIS (MYLAN, INC) · Firm: S-3 GROUP
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
BROWN-FORMAN CORPORATION via S-3 GROUP
2026 · third_quarter · Q3
Issues related to proposed FDA dietary guidelines for alcohol
Issues related to corporate tax policy, tariffs, including duty drawbacks
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Source: Senate LDA
| COUNCIL ON FOUNDATIONS INC. |
| 8 |
| 2025–2026 |
| CTIA - THE WIRELESSS ASSOCIATION | 8 | 2025–2026 |
| DAVITA, INC. | 8 | 2025–2026 |
| LOWE'S COMPANIES INC | 8 | 2025–2026 |
| MASSACHUSETTS INSTITUTE OF TECHNOLOGY | 8 | 2025–2026 |
| OSHKOSH CORPORATION | 8 | 2025–2026 |
| PNC FINANCIAL INC. | 8 | 2025–2026 |
| REPUBLIC SERVICES, INC. | 8 | 2025–2026 |
| VAPOR TECHNOLOGY ASSOCIATION | 8 | 2025–2026 |
| WALGREEN COMPANY | 8 | 2025–2026 |
| CONSUMER TECHNOLOGY ASSOCIATION | 7 | 2025–2026 |
| INTEL CORPORATION | 7 | 2025–2026 |
| KOCH GOVERNMENT AFFAIRS, LLC FKA KOCH COMPANIES PUBLIC SECTOR, LLC | 7 | 2025–2026 |
| T-MOBILE USA, INC. | 7 | 2025–2026 |
| HEALTH INDUSTRY DISTRIBUTORS ASSOCIATION | 6 | 2025 |
| PRUDENTIAL FINANCIAL INC | 6 | 2025–2026 |
| WALMART INC | 6 | 2025–2026 |
| BROWN-FORMAN CORPORATION | 4 | 2026 |
| BRUNSWICK CORPORATION | 4 | 2025 |
| EXPEDIA GROUP | 4 | 2025 |
| Fresenius Kabi | 1 | 2025 |
Issues related to drug pricing; pharmaceutical supply chain; modernization of prescribing information for physicians and pharmacists; Increasing Transparency in Generic Drug Applications, S.1302 and H.R. 1843; Part D Formulary Design and Generic Drug Testing
To amend the Federal Food, Drug, and Cosmetic Act to increase transparency in generic drug applications.
Client: VIATRIS (MYLAN, INC) · Firm: S-3 GROUP
Issues related to drug pricing; pharmaceutical supply chain; modernization of prescribing information for physicians and pharmacists; Increasing Transparency in Generic Drug Applications, S.1302 and H.R. 1843; Part D Formulary Design and Generic Drug Testing
Issues related to preventing organized retail crime, including the Combatting Organized Retail Crime Act: (H.R. 2853/S.1404)
Issues related to preventing organized retail crime, including the Combatting Organized Retail Crime Act: (H.R. 2853/S.1404)
Issues related to patent policy and reform, including to address patent thickets and FDA/PTO Coordination; S.527 Prescription Pricing for the People Act; S.1096 Preserve Access to Affordable Generics and Biosimilars Act; S.1041 Affordable Prescriptions for Patients Act
Issues related to patent policy and reform, including to address patent thickets and FDA/PTO Coordination; S.527 Prescription Pricing for the People Act; S.1096 Preserve Access to Affordable Generics and Biosimilars Act; S.1041 Affordable Prescriptions for Patients Act
Issues related to patent policy and reform, including to address patent thickets and FDA/PTO Coordination; S.527 Prescription Pricing for the People Act; S.1096 Preserve Access to Affordable Generics and Biosimilars Act; S.1041 Affordable Prescriptions for Patients Act
Preserve Access to Affordable Generics and Biosimilars Act
Client: VIATRIS (MYLAN, INC) · Firm: S-3 GROUP
Issues related to patent policy and reform, including to address patent thickets and FDA/PTO Coordination; S.527 Prescription Pricing for the People Act; S.1096 Preserve Access to Affordable Generics and Biosimilars Act; S.1041 Affordable Prescriptions for Patients Act
Preserve Access to Affordable Generics and Biosimilars Act
Client: VIATRIS (MYLAN, INC) · Firm: S-3 GROUP
Issues related to patent policy and reform, including to address patent thickets and FDA/PTO Coordination; S.527 Prescription Pricing for the People Act; S.1096 Preserve Access to Affordable Generics and Biosimilars Act; S.1041 Affordable Prescriptions for Patients Act
Preserve Access to Affordable Generics and Biosimilars Act
Client: VIATRIS (MYLAN, INC) · Firm: S-3 GROUP
Issues related to patent policy and reform, including to address patent thickets and FDA/PTO Coordination; S.527 Prescription Pricing for the People Act; S.1096 Preserve Access to Affordable Generics and Biosimilars Act; S.1041 Affordable Prescriptions for Patients Act
Increasing Transparency in Generic Drug Applications Act
Client: VIATRIS (MYLAN, INC) · Firm: S-3 GROUP
Issues related to drug pricing; pharmaceutical supply chain; modernization of prescribing information for physicians and pharmacists; Increasing Transparency in Generic Drug Applications, S.1302 and H.R. 1843; Part D Formulary Design and Generic Drug Testing
Increasing Transparency in Generic Drug Applications Act
Client: VIATRIS (MYLAN, INC) · Firm: S-3 GROUP
Issues related to drug pricing; pharmaceutical supply chain; modernization of prescribing information for physicians and pharmacists; Increasing Transparency in Generic Drug Applications, S.1302 and H.R. 1843; Part D Formulary Design and Generic Drug Testing
Increasing Transparency in Generic Drug Applications Act
Client: VIATRIS (MYLAN, INC) · Firm: S-3 GROUP
Issues related to drug pricing; pharmaceutical supply chain; modernization of prescribing information for physicians and pharmacists; Increasing Transparency in Generic Drug Applications, S.1302 and H.R. 1843; Part D Formulary Design and Generic Drug Testing
Issues related to preventing organized retail crime, including the Combatting Organized Retail Crime Act: (H.R. 2853/S.1404)
Issues related to preventing organized retail crime, including the Combatting Organized Retail Crime Act: (H.R. 2853/S.1404)
Issues related to patent policy and reform, including to address patent thickets and FDA/PTO Coordination; S.527 Prescription Pricing for the People Act; S.1096 Preserve Access to Affordable Generics and Biosimilars Act; S.1041 Affordable Prescriptions for Patients Act
Issues related to patent policy and reform, including to address patent thickets and FDA/PTO Coordination; S.527 Prescription Pricing for the People Act; S.1096 Preserve Access to Affordable Generics and Biosimilars Act; S.1041 Affordable Prescriptions for Patients Act
Issues related to patent policy and reform, including to address patent thickets and FDA/PTO Coordination; S.527 Prescription Pricing for the People Act; S.1096 Preserve Access to Affordable Generics and Biosimilars Act; S.1041 Affordable Prescriptions for Patients Act
To amend the Federal Food, Drug, and Cosmetic Act to increase transparency in generic drug applications.
Client: VIATRIS (MYLAN, INC) · Firm: S-3 GROUP
Issues related to drug pricing; pharmaceutical supply chain; modernizational of prescribing information for physicians and pharmacists; Increasing Trasnparency in Generic Drug Applications, S.1302 and H.R. 1843; Part D Formulary Design and Generic Drug Testing
To amend the Federal Food, Drug, and Cosmetic Act to increase transparency in generic drug applications.
Client: VIATRIS (MYLAN, INC) · Firm: S-3 GROUP
Issues related to drug pricing; pharmaceutical supply chain; modernization of prescribing information for physicians and pharmacists; Increasing Transparency in Generic Drug Applications, S.1302 and H.R. 1843; Part D Formulary Design and Generic Drug Testing
To amend the Federal Food, Drug, and Cosmetic Act to increase transparency in generic drug applications.
Client: VIATRIS (MYLAN, INC) · Firm: S-3 GROUP
Issues related to drug pricing; pharmaceutical supply chain; modernization of prescribing information for physicians and pharmacists; Increasing Transparency in Generic Drug Applications, S.1302 and H.R. 1843; Part D Formulary Design and Generic Drug Testing
To amend the Federal Food, Drug, and Cosmetic Act to increase transparency in generic drug applications.
Client: VIATRIS (MYLAN, INC) · Firm: S-3 GROUP
Issues related to drug pricing; pharmaceutical supply chain; modernization of prescribing information for physicians and pharmacists; Increasing Transparency in Generic Drug Applications, S.1302 and H.R. 1843; Part D Formulary Design and Generic Drug Testing
To amend the Federal Food, Drug, and Cosmetic Act to increase transparency in generic drug applications.
Client: VIATRIS (MYLAN, INC) · Firm: S-3 GROUP
Issues related to drug pricing; pharmaceutical supply chain; modernization of prescribing information for physicians and pharmacists; Increasing Transparency in Generic Drug Applications, S.1302 and H.R. 1843; Part D Formulary Design and Generic Drug Testing
To amend the Federal Food, Drug, and Cosmetic Act to increase transparency in generic drug applications.
Client: VIATRIS (MYLAN, INC) · Firm: S-3 GROUP
Issues related to drug pricing; pharmaceutical supply chain; modernization of prescribing information for physicians and pharmacists; Increasing Transparency in Generic Drug Applications, S.1302 and H.R. 1843; Part D Formulary Design and Generic Drug Testing
To amend the Federal Food, Drug, and Cosmetic Act to increase transparency in generic drug applications.
Client: VIATRIS (MYLAN, INC) · Firm: S-3 GROUP
Issues related to drug pricing; pharmaceutical supply chain; modernization of prescribing information for physicians and pharmacists; Increasing Transparency in Generic Drug Applications, S.1302 and H.R. 1843; Part D Formulary Design and Generic Drug Testing
Issues related to patent policy and reform, including to address patent thickets and FDA/PTO Coordination; S.527 Prescription Pricing for the People Act; S.1096 Preserve Access to Affordable Generics and Biosimilars Act; S.1041 Affordable Prescriptions for Patients Act
Issues related to patent policy and reform, including to address patent thickets and FDA/PTO Coordination; S.527 Prescription Pricing for the People Act; S.1096 Preserve Access to Affordable Generics and Biosimilars Act; S.1041 Affordable Prescriptions for Patients Act
Issues related to patent policy and reform, including to address patent thickets and FDA/PTO Coordination; S.527 Prescription Pricing for the People Act; S.1096 Preserve Access to Affordable Generics and Biosimilars Act; S.1041 Affordable Prescriptions for Patients Act
Issues related to patent policy and reform, including to address patent thickets and FDA/PTO Coordination; S.527 Prescription Pricing for the People Act; S.1096 Preserve Access to Affordable Generics and Biosimilars Act; S.1041 Affordable Prescriptions for Patients Act
Preserve Access to Affordable Generics and Biosimilars Act
Client: VIATRIS (MYLAN, INC) · Firm: S-3 GROUP
Issues related to patent policy and reform, including to address patent thickets and FDA/PTO Coordination; S.527 Prescription Pricing for the People Act; S.1096 Preserve Access to Affordable Generics and Biosimilars Act; S.1041 Affordable Prescriptions for Patients Act
Preserve Access to Affordable Generics and Biosimilars Act
Client: VIATRIS (MYLAN, INC) · Firm: S-3 GROUP
Issues related to patent policy and reform, including to address patent thickets and FDA/PTO Coordination; S.527 Prescription Pricing for the People Act; S.1096 Preserve Access to Affordable Generics and Biosimilars Act; S.1041 Affordable Prescriptions for Patients Act
Preserve Access to Affordable Generics and Biosimilars Act
Client: VIATRIS (MYLAN, INC) · Firm: S-3 GROUP
Issues related to patent policy and reform, including to address patent thickets and FDA/PTO Coordination; S.527 Prescription Pricing for the People Act; S.1096 Preserve Access to Affordable Generics and Biosimilars Act; S.1041 Affordable Prescriptions for Patients Act
Preserve Access to Affordable Generics and Biosimilars Act
Client: VIATRIS (MYLAN, INC) · Firm: S-3 GROUP
Issues related to patent policy and reform, including to address patent thickets and FDA/PTO Coordination; S.527 Prescription Pricing for the People Act; S.1096 Preserve Access to Affordable Generics and Biosimilars Act; S.1041 Affordable Prescriptions for Patients Act
Increasing Transparency in Generic Drug Applications Act
Client: VIATRIS (MYLAN, INC) · Firm: S-3 GROUP
Issues related to drug pricing; pharmaceutical supply chain; modernization of prescribing information for physicians and pharmacists; Increasing Transparency in Generic Drug Applications, S.1302 and H.R. 1843; Part D Formulary Design and Generic Drug Testing
Increasing Transparency in Generic Drug Applications Act
Client: VIATRIS (MYLAN, INC) · Firm: S-3 GROUP
Issues related to drug pricing; pharmaceutical supply chain; modernization of prescribing information for physicians and pharmacists; Increasing Transparency in Generic Drug Applications, S.1302 and H.R. 1843; Part D Formulary Design and Generic Drug Testing
Increasing Transparency in Generic Drug Applications Act
Client: VIATRIS (MYLAN, INC) · Firm: S-3 GROUP
Issues related to drug pricing; pharmaceutical supply chain; modernization of prescribing information for physicians and pharmacists; Increasing Transparency in Generic Drug Applications, S.1302 and H.R. 1843; Part D Formulary Design and Generic Drug Testing
Increasing Transparency in Generic Drug Applications Act
Client: VIATRIS (MYLAN, INC) · Firm: S-3 GROUP
Issues related to drug pricing; pharmaceutical supply chain; modernization of prescribing information for physicians and pharmacists; Increasing Transparency in Generic Drug Applications, S.1302 and H.R. 1843; Part D Formulary Design and Generic Drug Testing
Increasing Transparency in Generic Drug Applications Act
Client: VIATRIS (MYLAN, INC) · Firm: S-3 GROUP
Issues related to drug pricing; pharmaceutical supply chain; modernization of prescribing information for physicians and pharmacists; Increasing Transparency in Generic Drug Applications, S.1302 and H.R. 1843; Part D Formulary Design and Generic Drug Testing
Increasing Transparency in Generic Drug Applications Act
Client: VIATRIS (MYLAN, INC) · Firm: S-3 GROUP
Issues related to drug pricing; pharmaceutical supply chain; modernization of prescribing information for physicians and pharmacists; Increasing Transparency in Generic Drug Applications, S.1302 and H.R. 1843; Part D Formulary Design and Generic Drug Testing
Increasing Transparency in Generic Drug Applications Act
Client: VIATRIS (MYLAN, INC) · Firm: S-3 GROUP
Issues related to drug pricing; pharmaceutical supply chain; modernizational of prescribing information for physicians and pharmacists; Increasing Trasnparency in Generic Drug Applications, S.1302 and H.R. 1843; Part D Formulary Design and Generic Drug Testing
Issues related to patent policy and reform, including to address patent thickets and FDA/PTO Coordination; S.527 Prescription Pricing for the People Act; S.1096 Preserve Access to Affordable Generics and Biosimilars Act; S.1041 Affordable Prescriptions for Patients Act
Issues related to patent policy and reform, including to address patent thickets and FDA/PTO Coordination; S.527 Prescription Pricing for the People Act; S.1096 Preserve Access to Affordable Generics and Biosimilars Act; S.1041 Affordable Prescriptions for Patients Act
Issues related to patent policy and reform, including to address patent thickets and FDA/PTO Coordination; S.527 Prescription Pricing for the People Act; S.1096 Preserve Access to Affordable Generics and Biosimilars Act; S.1041 Affordable Prescriptions for Patients Act
Issues related to patent policy and reform, including to address patent thickets and FDA/PTO Coordination; S.527 Prescription Pricing for the People Act; S.1096 Preserve Access to Affordable Generics and Biosimilars Act; S.1041 Affordable Prescriptions for Patients Act
2026 · third_quarter · Q3
US manufacturing and international competitiveness
US manufacturing and international competitiveness
US manufacturing and international competitiveness
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PNC FINANCIAL INC. via S-3 GROUP
2026 · third_quarter · Q3
Monitor issues impacting the financial services industry
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
VIATRIS (MYLAN, INC) via S-3 GROUP
2026 · third_quarter · Q3
Issues related to patent policy and reform, including to address patent thickets and FDA/PTO Coordination; S.527 Prescription Pricing for the People Act; S.1096 Preserve Access to Affordable Generics and Biosimilars Act; S.1041 Affordable Prescriptions for Patients Act
Issues related to drug pricing; pharmaceutical supply chain; modernization of prescribing information for physicians and pharmacists; Increasing Transparency in Generic Drug Applications, S.1302 and H.R. 1843; Part D Formulary Design and Generic Drug Testing
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
BLOOM ENERGY CORPORATION via S-3 GROUP
2026 · third_quarter · Q3
Issues related to fuel cell tax credits
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
COUNCIL ON FOUNDATIONS INC. via S-3 GROUP
2026 · third_quarter · Q3
Strategies and policy advice on tax policy matters with respect to the philanthropic sector
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
BRIGHTHOUSE SERVICES LLC via S-3 GROUP
2026 · third_quarter · Q3
General issues related to retirement planning, including annuities and life insurance; taxation; cybersecurity; and consumer privacy
General issues related to retirement planning, including annuities and life insurance; taxation; cybersecurity; and consumer privacy
General issues related to retirement planning, including annuities and life insurance; taxation; cybersecurity; and consumer privacy
PATTERN ENERGY GROUP SERVICES LP via S-3 GROUP
2026 · third_quarter · Q3
Issues regarding renewable energy and electronic transmission projects
Filing targets: Energy, Dept of, HOUSE OF REPRESENTATIVES, SENATE
REPUBLIC SERVICES, INC. via S-3 GROUP
2026 · third_quarter · Q3
Issues related to waste management, recycling and circularity, environmental policy, and taxation
Issues related to waste management, recycling and circularity, environmental policy, and taxation
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CENTER ON BUDGET AND POLICY PRIORITIES via S-3 GROUP
2026 · third_quarter · Q3
Issues related to tax reform
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
2026 · third_quarter · Q3
Issues related to dialysis payment policy, including End Stage Renal Disease (ESRD) Perspective Payment System (PPS)
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
AMERICAN PSYCHOLOGICAL ASSOCIATION SERVICES, INC. via S-3 GROUP
2026 · third_quarter · Q3
Issues related to reimbursement for psychologists in designated health professional shortage areas; and issues related to reimbursement for psychological and neuropsychological testing in Medicare
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
MASSACHUSETTS INSTITUTE OF TECHNOLOGY via S-3 GROUP
2026 · third_quarter · Q3
Issues related to higher education
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
LOWE'S COMPANIES INC. via S-3 GROUP
2026 · third_quarter · Q3
Issues related to corporate tax reform
Issues related to corporate tax reform
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
VAPOR TECHNOLOGY ASSOCIATION via S-3 GROUP
2026 · third_quarter · Q3
Issues relating to the regulation of vapor products
Issues relating to the regulation of vapor products
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
WALGREEN COMPANY via S-3 GROUP
2026 · third_quarter · Q3
Issues related to the provider status of pharmacists under Medicare Part B
Issues related to preventing organized retail crime, including the Combatting Organized Retail Crime Act: (H.R. 2853/S.1404)
Issues related to pharmacy, pharmacist provider status, pharmacy benefit managers, Medicare reimbursement, and pharmaceutical supply chain transparency
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
INTEL CORPORATION via S-3 GROUP
2026 · third_quarter · Q3
Issues related to trade and tariffs
Issues related to support for domestic chipmakers in NDAA
Issues related to Inter Partes Review and patent litigation at the ITC
CONSUMER TECHNOLOGY ASSOCIATION via S-3 GROUP
2026 · third_quarter · Q3
General educational meetings on policy issues impacting tech platforms
Monitor issues related to consumer data privacy, and children's privacy
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CTIA THE WIRELESS ASSOCIATION via S-3 GROUP
2026 · third_quarter · Q3
Issues related to wireless policy, including spectrum, broadband funding, 5G, and privacy; issues related to the use of contraband phones in correctional facilities; issues related to artificial intelligence.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
KOCH GOVERNMENT AFFAIRS, LLC FKA KOCH COMPANIES PUBLIC SECTOR, LLC via S-3 GROUP
2026 · third_quarter · Q3
Legislative issues related to energy and the environment; issues related to congressional funding
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
T-MOBILE USA, INC. via S-3 GROUP
2026 · third_quarter · Q3
Issues relating to the repurposing of spectrum
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
AMERICAN PSYCHOLOGICAL ASSOCIATION SERVICES, INC. via S-3 GROUP
2026 · second_quarter · 2A
Issues related to reimbursement for psychologists in designated health professional shortage areas; and issues related to reimbursement for psychological and neuropsychological testing in Medicare
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
AMERICAN PSYCHOLOGICAL ASSOCIATION SERVICES, INC. via S-3 GROUP
2026 · second_quarter · 2A
Issues related to reimbursement for psychologists in designated health professional shortage areas; and issues related to reimbursement for psychological and neuropsychological testing in Medicare
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
BROWN-FORMAN CORPORATION via S-3 GROUP
2026 · second_quarter · Q2
Issues related to proposed FDA dietary guidelines for alcohol
Issues related to corporate tax policy, tariffs, including duty drawbacks
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
OSHKOSH CORPORATION via S-3 GROUP
2026 · second_quarter · Q2
US manufacturing and international competitiveness
US manufacturing and international competitiveness
US manufacturing and international competitiveness
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PNC FINANCIAL INC. via S-3 GROUP
2026 · second_quarter · Q2
Monitor issues impacting the financial services industry
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
VIATRIS (MYLAN, INC) via S-3 GROUP
2026 · second_quarter · Q2
Issues related to patent policy and reform, including to address patent thickets and FDA/PTO Coordination; S.527 Prescription Pricing for the People Act; S.1096 Preserve Access to Affordable Generics and Biosimilars Act; S.1041 Affordable Prescriptions for Patients Act
Issues related to drug pricing; pharmaceutical supply chain; modernization of prescribing information for physicians and pharmacists; Increasing Transparency in Generic Drug Applications, S.1302 and H.R. 1843; Part D Formulary Design and Generic Drug Testing
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
BLOOM ENERGY CORPORATION via S-3 GROUP
2026 · second_quarter · Q2
Issues related to fuel cell tax credits
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
COUNCIL ON FOUNDATIONS INC. via S-3 GROUP
2026 · second_quarter · Q2
Strategies and policy advice on tax policy matters with respect to the philanthropic sector
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
BRIGHTHOUSE SERVICES LLC via S-3 GROUP
2026 · second_quarter · Q2
General issues related to retirement planning, including annuities and life insurance; taxation; cybersecurity; and consumer privacy
General issues related to retirement planning, including annuities and life insurance; taxation; cybersecurity; and consumer privacy
General issues related to retirement planning, including annuities and life insurance; taxation; cybersecurity; and consumer privacy
PATTERN ENERGY GROUP SERVICES LP via S-3 GROUP
2026 · second_quarter · Q2
Issues regarding renewable energy and electronic transmission projects
Filing targets: Energy, Dept of, HOUSE OF REPRESENTATIVES, SENATE
REPUBLIC SERVICES, INC. via S-3 GROUP
2026 · second_quarter · Q2
Issues related to waste management, recycling and circularity, environmental policy, and taxation
Issues related to waste management, recycling and circularity, environmental policy, and taxation
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CENTER ON BUDGET AND POLICY PRIORITIES via S-3 GROUP
2026 · second_quarter · Q2
Issues related to tax reform
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
2026 · second_quarter · Q2
Issues related to dialysis payment policy, including End Stage Renal Disease (ESRD) Perspective Payment System (PPS)
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
AMERICAN PSYCHOLOGICAL ASSOCIATION SERVICES, INC. via S-3 GROUP
2026 · second_quarter · Q2
Issues related to reimbursement for psychologists in designated health professional shortage areas; and issues related to reimbursement for psychological and neuropsychological testing in Medicare
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
MASSACHUSETTS INSTITUTE OF TECHNOLOGY via S-3 GROUP
2026 · second_quarter · Q2
Issues related to higher education
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
LOWE'S COMPANIES INC. via S-3 GROUP
2026 · second_quarter · Q2
Issues related to corporate tax reform
Issues related to corporate tax reform
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
VAPOR TECHNOLOGY ASSOCIATION via S-3 GROUP
2026 · second_quarter · Q2
Issues relating to the regulation of vapor products
Issues relating to the regulation of vapor products
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
WALGREEN COMPANY via S-3 GROUP
2026 · second_quarter · Q2
Issues related to preventing organized retail crime, including the Combatting Organized Retail Crime Act: (H.R. 2853/S.1404)
Issues related to the provider status of pharmacists under Medicare Part B
Issues related to pharmacy, pharmacist provider status, pharmacy benefit managers, Medicare reimbursement, and pharmaceutical supply chain transparency
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
INTEL CORPORATION via S-3 GROUP
2026 · second_quarter · Q2
Issues related to support for domestic chipmakers in NDAA
Issues related to semiconductor competitiveness
Issues related to trade and tariffs
CONSUMER TECHNOLOGY ASSOCIATION via S-3 GROUP
2026 · second_quarter · Q2
Monitor issues related to consumer data privacy, and children's privacy
General educational meetings on policy issues impacting tech platforms
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CTIA THE WIRELESS ASSOCIATION via S-3 GROUP
2026 · second_quarter · Q2
Issues related to wireless policy, including spectrum, broadband funding, 5G, and privacy; issues related to the use of contraband phones in correctional facilities; issues related to artificial intelligence.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
KOCH GOVERNMENT AFFAIRS, LLC FKA KOCH COMPANIES PUBLIC SECTOR, LLC via S-3 GROUP
2026 · second_quarter · Q2
Legislative issues related to energy and the environment; issues related to congressional funding
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
T-MOBILE USA, INC. via S-3 GROUP
2026 · second_quarter · Q2
Issues relating to the repurposing of spectrum
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
BROWN-FORMAN CORPORATION via S-3 GROUP
2026 · first_quarter · Q1
Issues related to proposed FDA dietary guidelines for alcohol
Issues related to corporate tax policy, tariffs, including duty drawbacks
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
OSHKOSH CORPORATION via S-3 GROUP
2026 · first_quarter · Q1
US manufacturing and international competitiveness
US manufacturing and international competitiveness
US manufacturing and international competitiveness
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PNC FINANCIAL INC. via S-3 GROUP
2026 · first_quarter · Q1
Monitor issues impacting the financial services industry
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
VIATRIS (MYLAN, INC) via S-3 GROUP
2026 · first_quarter · Q1
Issues related to patent policy and reform, including to address patent thickets and FDA/PTO Coordination; S.527 Prescription Pricing for the People Act; S.1096 Preserve Access to Affordable Generics and Biosimilars Act; S.1041 Affordable Prescriptions for Patients Act
Issues related to drug pricing; pharmaceutical supply chain; modernization of prescribing information for physicians and pharmacists; Increasing Transparency in Generic Drug Applications, S.1302 and H.R. 1843; Part D Formulary Design and Generic Drug Testing
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
BLOOM ENERGY CORPORATION via S-3 GROUP
2026 · first_quarter · Q1
Issues related to fuel cell tax credits
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
2026 · first_quarter · Q1
Issues related to trade
Issues related to privacy
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
COUNCIL ON FOUNDATIONS INC. via S-3 GROUP
2026 · first_quarter · Q1
Strategies and policy advice on tax policy matters with respect to the philanthropic sector
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
BRIGHTHOUSE SERVICES LLC via S-3 GROUP
2026 · first_quarter · Q1
General issues related to retirement planning, including annuities and life insurance; taxation; cybersecurity; and consumer privacy
General issues related to retirement planning, including annuities and life insurance; taxation; cybersecurity; and consumer privacy
General issues related to retirement planning, including annuities and life insurance; taxation; cybersecurity; and consumer privacy
PATTERN ENERGY GROUP SERVICES LP via S-3 GROUP
2026 · first_quarter · Q1
Issues regarding renewable energy and electronic transmission projects
Filing targets: Energy, Dept of, HOUSE OF REPRESENTATIVES, SENATE
PATTERN ENERGY GROUP SERVICES LP via S-3 GROUP
2026 · first_quarter · Q1
Issues regarding renewable energy and electronic transmission projects
Filing targets: Energy, Dept of, HOUSE OF REPRESENTATIVES, SENATE
PRUDENTIAL FINANCIAL, INC. via S-3 GROUP
2026 · first_quarter · 1T
Issues related to financial services reform
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
REPUBLIC SERVICES, INC. via S-3 GROUP
2026 · first_quarter · Q1
Issues related to waste management, recycling and circularity, environmental policy, and taxation
Issues related to waste management, recycling and circularity, environmental policy, and taxation
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CENTER ON BUDGET AND POLICY PRIORITIES via S-3 GROUP
2026 · first_quarter · Q1
Issues related to tax reform
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
2026 · first_quarter · Q1
Issues related to dialysis payment policy, including End Stage Renal Disease (ESRD) Perspective Payment System (PPS)
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
AMERICAN PSYCHOLOGICAL ASSOCIATION SERVICES, INC. via S-3 GROUP
2026 · first_quarter · Q1
Issues related to reimbursement for psychologists in designated health professional shortage areas; and issues related to reimbursement for psychological and neuropsychological testing in Medicare
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
MASSACHUSETTS INSTITUTE OF TECHNOLOGY via S-3 GROUP
2026 · first_quarter · Q1
Issues related to higher education
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
LOWE'S COMPANIES INC. via S-3 GROUP
2026 · first_quarter · Q1
Issues related to corporate tax reform
Issues related to corporate tax reform
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
VAPOR TECHNOLOGY ASSOCIATION via S-3 GROUP
2026 · first_quarter · Q1
Issues relating to the regulation of vapor products
Issues relating to the regulation of vapor products
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
WALGREEN COMPANY via S-3 GROUP
2026 · first_quarter · Q1
Issues related to pharmacy, pharmacist provider status, and Medicare reimbursement
Issues related to the provider status of pharmacists under Medicare Part B
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
INTEL CORPORATION via S-3 GROUP
2026 · first_quarter · Q1
Issues related to funding for CHIPS Act
Issues related to trade and tariffs
Issues related to semiconductor competitiveness
CONSUMER TECHNOLOGY ASSOCIATION via S-3 GROUP
2026 · first_quarter · Q1
General educational meetings on policy issues impacting tech platforms
Monitor issues related to consumer data privacy, and children's privacy
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CONSUMER TECHNOLOGY ASSOCIATION via S-3 GROUP
2026 · first_quarter · Q1
Monitor issues related to consumer data privacy, and children's privacy
General educational meetings on policy issues impacting tech platforms
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CTIA THE WIRELESS ASSOCIATION via S-3 GROUP
2026 · first_quarter · Q1
Issues related to wireless policy, including spectrum, broadband funding, 5G, and privacy; issues related to the use of contraband phones in correctional facilities, including End Cells in Cells; Cooper Davis Act
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
KOCH GOVERNMENT AFFAIRS, LLC FKA KOCH COMPANIES PUBLIC SECTOR, LLC via S-3 GROUP
2026 · first_quarter · Q1
Legislative issues related to energy and the environment; issues related to congressional funding
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
T-MOBILE USA, INC. via S-3 GROUP
2026 · first_quarter · Q1
Issues relating to the repurposing of spectrum
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
BROWN-FORMAN CORPORATION via S-3 GROUP
2026 · first_quarter · RR
Issues related to corporate tax policy, tariffs, including duty drawbacks; and proposed FDA dietary guidelines for alcohol
Issues related to corporate tax policy, tariffs, including duty drawbacks; and proposed FDA dietary guidelines for alcohol
Issues related to corporate tax policy, tariffs, including duty drawbacks; and proposed FDA dietary guidelines for alcohol
HEALTH INDUSTRY DISTRIBUTORS ASSOCIATION via S-3 GROUP
2025 · fourth_quarter · 4T
Issues related to the distribution of health care products, trade policy, and tariffs
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PNC FINANCIAL INC. via S-3 GROUP
2025 · fourth_quarter · Q4
Monitor issues impacting the financial services industry
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
VIATRIS (MYLAN, INC) via S-3 GROUP
2025 · fourth_quarter · 4A
Issues related to drug pricing; pharmaceutical supply chain; modernization of prescribing information for physicians and pharmacists; Increasing Transparency in Generic Drug Applications, S.1302 and H.R. 1843; Part D Formulary Design and Generic Drug Testing
Issues related to patent policy and reform, including to address patent thickets and FDA/PTO Coordination; S.527 Prescription Pricing for the People Act; S.1096 Preserve Access to Affordable Generics and Biosimilars Act; S.1041 Affordable Prescriptions for Patients Act
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
2025 · fourth_quarter · Q4
Issues related to trade
Issues related to privacy
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
COUNCIL ON FOUNDATIONS INC. via S-3 GROUP
2025 · fourth_quarter · Q4
Strategies and policy advice on tax policy matters with respect to the philanthropic sector
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PATTERN ENERGY GROUP SERVICES LP via S-3 GROUP
2025 · fourth_quarter · Q4
Issues regarding renewable energy and electronic transmission projects
Filing targets: Energy, Dept of, HOUSE OF REPRESENTATIVES, SENATE
REPUBLIC SERVICES, INC. via S-3 GROUP
2025 · fourth_quarter · Q4
Issues related to waste management, recycling and circularity, environmental policy, and taxation
Issues related to waste management, recycling and circularity, environmental policy, and taxation
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CENTER ON BUDGET AND POLICY PRIORITIES via S-3 GROUP
2025 · fourth_quarter · Q4
Issues related to tax reform
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
2025 · fourth_quarter · Q4
Issues related to dialysis payment policy, including End Stage Renal Disease (ESRD) Perspective Payment System (PPS)
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
AMERICAN PSYCHOLOGICAL ASSOCIATION SERVICES, INC. via S-3 GROUP
2025 · fourth_quarter · Q4
Issues related to reimbursement for psychologists in designated health professional shortage areas; and issues related to reimbursement for psychological and neuropsychological testing in Medicare
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
LOWE'S COMPANIES INC. via S-3 GROUP
2025 · fourth_quarter · Q4
Issues related to corporate tax reform
Issues related to corporate tax reform
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
VAPOR TECHNOLOGY ASSOCIATION via S-3 GROUP
2025 · fourth_quarter · Q4
Issues relating to the regulation of vapor products
Issues relating to the regulation of vapor products
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
WALGREEN COMPANY via S-3 GROUP
2025 · fourth_quarter · Q4
Issues related to pharmacy, pharmacist provider status, and Medicare reimbursement
Issues related to the provider status of pharmacists under Medicare Part B
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
INTEL CORPORATION via S-3 GROUP
2025 · fourth_quarter · Q4
Issues related to funding for CHIPS Act
Issues related to support for domestic chipmakers in NDAA
Issues related to semiconductor competitiveness
PRUDENTIAL FINANCIAL, INC. via S-3 GROUP
2025 · fourth_quarter · Q4
Issues related to financial services reform
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CONSUMER TECHNOLOGY ASSOCIATION via S-3 GROUP
2025 · fourth_quarter · Q4
General educational meetings on policy issues impacting tech platforms
Monitor issues related to consumer data privacy, and children's privacy
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CTIA THE WIRELESS ASSOCIATION via S-3 GROUP
2025 · fourth_quarter · Q4
Issues related to wireless policy, including spectrum, broadband funding, 5G, and privacy; issues related to the use of contraband phones in correctional facilities, including End Cells in Cells; Cooper Davis Act
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
T-MOBILE USA, INC. via S-3 GROUP
2025 · fourth_quarter · Q4
Issues relating to the repurposing of spectrum
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
MASSACHUSETTS INSTITUTE OF TECHNOLOGY via S-3 GROUP
2025 · fourth_quarter · Q4
Issues related to higher education
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
KOCH GOVERNMENT AFFAIRS, LLC FKA KOCH COMPANIES PUBLIC SECTOR, LLC via S-3 GROUP
2025 · fourth_quarter · Q4
Legislative issues related to energy and the environment; issues related to congressional funding
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
BRIGHTHOUSE SERVICES LLC via S-3 GROUP
2025 · fourth_quarter · Q4
General issues related to retirement planning, including annuities and life insurance; taxation; cybersecurity; and consumer privacy
General issues related to retirement planning, including annuities and life insurance; taxation; cybersecurity; and consumer privacy
General issues related to retirement planning, including annuities and life insurance; taxation; cybersecurity; and consumer privacy
BLOOM ENERGY CORPORATION via S-3 GROUP
2025 · fourth_quarter · Q4
Issues related to fuel cell tax credits
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
OSHKOSH CORPORATION via S-3 GROUP
2025 · fourth_quarter · Q4
US manufacturing and international competitiveness
US manufacturing and international competitiveness
US manufacturing and international competitiveness
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
HEALTH INDUSTRY DISTRIBUTORS ASSOCIATION via S-3 GROUP
2025 · fourth_quarter · Q4
Issues related to the distribution of health care products, trade policy, and tariffs
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
VIATRIS (MYLAN, INC) via S-3 GROUP
2025 · fourth_quarter · Q4
Issues related to drug pricing; pharmaceutical supply chain; modernization of prescribing information for physicians and pharmacists; Increasing Transparency in Generic Drug Applications, S.1302 and H.R. 1843; Part D Formulary Design and Generic Drug Testing
Issues related to patent policy and reform, including to address patent thickets and FDA/PTO Coordination; S.527 Prescription Pricing for the People Act; S.1096 Preserve Access to Affordable Generics and Biosimilars Act; S.1041 Affordable Prescriptions for Patients Act
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
OSHKOSH CORPORATION via S-3 GROUP
2025 · third_quarter · Q3
US manufacturing and international competitiveness
US manufacturing and international competitiveness
US manufacturing and international competitiveness
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PNC FINANCIAL INC. via S-3 GROUP
2025 · third_quarter · Q3
Monitor issues impacting the financial services industry
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
VIATRIS (MYLAN, INC) via S-3 GROUP
2025 · third_quarter · Q3
Issues related to drug pricing; pharmaceutical supply chain; modernization of prescribing information for physicians and pharmacists; Increasing Transparency in Generic Drug Applications, S.1302 and H.R. 1843; Part D Formulary Design and Generic Drug Testing
Issues related to patent policy and reform, including to address patent thickets and FDA/PTO Coordination; S.527 Prescription Pricing for the People Act; S.1096 Preserve Access to Affordable Generics and Biosimilars Act; S.1041 Affordable Prescriptions for Patients Act
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
BLOOM ENERGY CORPORATION via S-3 GROUP
2025 · third_quarter · Q3
Issues related to fuel cell tax credits
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
2025 · third_quarter · Q3
Issues related to trade
Issues related to privacy
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
General issues related to retirement planning, including annuities and life insurance; taxation; cybersecurity; and consumer privacy
General issues related to retirement planning, including annuities and life insurance; taxation; cybersecurity; and consumer privacy
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues related to R&D tax credit
Issues related to funding for CHIPS Act
Issues related to semiconductor competitiveness
Issues in support for STEM
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
General issues related to retirement planning, including annuities and life insurance; taxation; cybersecurity; and consumer privacy
General issues related to retirement planning, including annuities and life insurance; taxation; cybersecurity; and consumer privacy
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues related to funding for CHIPS Act
Issues related to R&D tax credit
Issues in support for STEM
Issues related to Inter Partes Review and patent litigation at the ITC
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
General issues related to retirement planning, including annuities and life insurance; taxation; cybersecurity; and consumer privacy
General issues related to retirement planning, including annuities and life insurance; taxation; cybersecurity; and consumer privacy
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues related to support for domestic chipmakers in NDAA
Issues in support of STEM
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues in support of STEM
Issues related to R&D tax credit
Issues related to trade and tariffs
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
General issues related to retirement planning, including annuities and life insurance; taxation; cybersecurity; and consumer privacy
General issues related to retirement planning, including annuities and life insurance; taxation; cybersecurity; and consumer privacy
Filing targets: HOUSE OF REPRESENTATIVES, SENATE